Novartis Bolsters Hep C Pipeline With Human Genome Sciences Collaboration

Agreement gives Novartis rights to Albuferon, a Phase III interferon. In a separate agreement with Cytopia, Novartis will develop JAK3 inhibitors for autoimmune diseases and transplant rejection.